Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an update.
Rhythm Biosciences Ltd has announced a strategic pilot program for its geneTypeTM platform in partnership with a leading Australian pathology provider. This collaboration marks the first domestic pilot since Rhythm’s acquisition of geneType and aims to expand patient access to geneTypeTM tests through established clinical pathways. The partnership is expected to facilitate the commercial growth of geneTypeTM, enhancing Rhythm’s position in the predictive cancer diagnostics industry and creating opportunities for increased revenue.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest stages. Rhythm Biosciences is committed to collaborating with global partners for the commercialization and distribution of their diagnostic solutions.
Average Trading Volume: 309,184
Technical Sentiment Signal: Sell
Current Market Cap: A$17.71M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.